Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Titan BiotechBOM:524717 +0.70%51 Return-on-Tangible-Asset is 20.31% as of Jun. 2026, which is 43% above its 10-year median of 14.19. GuruFocus rates BOM:524717 with a GF Score™ of 51/100 and a GF Value™ of ₹162.06 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,414 Biotechnology companies, Titan Biotech ranks better than 93.92% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Titan Biotech's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹434 Mil. Titan Biotech's average total tangible assets for the quarter that ended in Jun. 2026 was ₹2,138 Mil. Therefore, Titan Biotech's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 20.31%.
The historical rank and industry rank for Titan Biotech's Return-on-Tangible-Asset or its related term are showing as below:
BOM:524717'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 4.68 Med: 14.19 Max: 34.36
Current: 17.2
During the past 13 years, Titan Biotech's highest Return-on-Tangible-Asset was 34.36%. The lowest was 4.68%. And the median was 14.19%.
BOM:524717's Return-on-Tangible-Asset is ranked better than 93.92% of 1414
companies
in the Biotechnology industry
Industry Median: -35.985
vs BOM:524717: 17.20
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Titan Biotech Return-on-Tangible-Asset Related Terms
Titan Biotech Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Titan Biotech's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524717 vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Titan Biotech's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Titan Biotech Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Titan Biotech's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Titan Biotech's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 20.31% mean?
Titan Biotech (BOM:524717) has a Return-on-Tangible-Asset of 20.31% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Titan Biotech and its competitors. This is 43% above median its historical median of 14.19. Over the past decade, Titan Biotech's Return-on-Tangible-Asset has ranged from 4.68 to 34.36. According to the industry distribution chart, Titan Biotech ranks #86 out of 1414 companies in the Biotechnology industry, placing it in the top 6.1%.
Is Titan Biotech's Return-on-Tangible-Asset too high?
Titan Biotech's current Return-on-Tangible-Asset of 20.31% is 43% above median its 10-year median of 14.19. Over the past 10 years, this metric has ranged from a low of 4.68 to a high of 34.36. Based on the distribution chart, Titan Biotech ranks #86 out of 1414 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Titan Biotech has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Titan Biotech ranks #86 out of 1414 companies for Return-on-Tangible-Asset. This places Titan Biotech in the top 6% of its industry — outperforming the majority of peers. Historically, Titan Biotech's own Return-on-Tangible-Asset has ranged from 4.68 to 34.36 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Titan Biotech and its competitors. Titan Biotech's current Return-on-Tangible-Asset is 20.31%, which is 43% above median its own 10-year median of 14.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹162.06, compared to a current price of ₹382.55 — trading 136.1% above its estimated fair value. The current Return-on-Tangible-Asset is 20.31%, which is 43% above median its 10-year median of 14.19. Titan Biotech's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current Return-on-Tangible-Asset is 20.31% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Titan Biotech (BOM:524717) Overvalued in 2026?
Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued.
The current stock price of ₹382.55 is trading 136.1% above its estimated GF Value™ of ₹162.06.
GuruFocus considers Titan Biotech to be Significantly Overvalued.
Key valuation signals for BOM:524717:
Return-on-Tangible-Asset: 20.31% (43% above median its 10-year median of 14.19)
GF Value™: ₹162.06 vs. price of ₹382.55 (136.1% above fair value)
No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
51GF Score
Get the complete analysis for BOM:524717
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524717 has been successfully added to your 
